Asymmetrical cortical vessel sign predicts prognosis after acute ischemic stroke

Brain Behav. 2020 Jul;10(7):e01657. doi: 10.1002/brb3.1657. Epub 2020 May 20.

Abstract

Introduction: To assess whether the asymmetrical cortical vessel sign (ACVS) on susceptibility-weighted imaging (SWI) could predict 90-day poor outcomes in anterior circulation acute ischemic stroke (AIS) patients treated with recombinant tissue plasminogen activator (r-tPA).

Methods: Clinical data of consecutive patients with anterior circulation AIS treated with r-tPA were retrospectively analyzed. Clinical variables included age, sex, vascular risk factors, NIHSS score, onset to treatment time, and initial hematologic and neuroimaging findings. Follow-up was performed 90 days after onset. Poor outcome was defined as a modified Rankin scale (mRS) ≥3 at 90 days.

Results: A total of 145 patients were included, 35 (24.1%) patients presented with ACVS (≥Grade 1) on SWI. Fifty-three (36.6%) patients had a poor outcome at 90 days. ACVS (≥Grade 1) occurred in 21 (39.6%) patients with poor outcome compared with 14 (15.2%) patients with favorable outcome (p = .001). Univariate analysis indicated that age, NIHSS score on admission, previous stroke, hemorrhagic transformation, severe intracranial large artery stenosis or occlusion (SILASO), and ACVS were associated with 90-day poor outcome (p < .05). Since SILASO and ACVS were highly correlated and ACVS had different grades, we used three logistic regression models. Results from the three models showed that ACVS was associated with 90-day poor outcome.

Conclusions: In r-tPA-treated patients with anterior circulation AIS, ACVS might be a helpful neuroimaging predictor for poor outcome at 90 days.

Keywords: acute ischemic stroke; asymmetrical cortical vessel sign; intravenous thrombolysis; outcome; susceptibility-weighted imaging.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Ischemia / diagnosis*
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / pathology
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Ischemic Stroke / diagnosis*
  • Ischemic Stroke / drug therapy*
  • Ischemic Stroke / pathology
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Tissue Plasminogen Activator / therapeutic use*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator